Innate Pharma : Un 3ème actif entre en clinique, l’IPH5401
>IPH5401 entre en phase 1 en oncologie en combinaison avec l’IMFINZI d’Astrazeneca - Innate Pharma annonce ce matin que son IPH5401 entre en phase 1 en combinaison avec l’IMFINZI d’Astrazeneca (anti PDL1) dans les tumeurs solides (notamment le cancer du poumon NSCLC et le cancer du foie), l’étude se nomme STELLAR-001 et comporte une escalade de doses du traitement (3 doses testées). Cette annonce est en ligne avec le plan de développement de l’IPH5401 annoncé en début...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.